Can-Fite BioPharma Ltd. announced that positive Phase 2a study data for Namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC) has been accepted for poster presentation at the ESMO Congress 2026. The study demonstrated durable disease stabilization and encouraging survival outcomes in patients who had progressed following prior standard therapies. The company is planning a Phase 2b study to evaluate Namodenoson in combination with chemotherapy. Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases.
